Enlivex Therapeutics Ltd.ENLV

$0.62+0.00 (+0.60%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$30M

Micro-cap

+64%

2016 — today

10-Year Price

-99%

2016 — today

52-Week Range

$0.62$1.82

Current $0.62· 0%

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Valuation in context

P/E ratio

0.0

Near historic high

Near historic highs — last 10 years

P/B ratio

0.0

Near historic low

Near historic low — last 10 years

FCF Yield

-37.0%

Above average

Above the 10-year average

Free · No credit card needed

Get alerted when ENLV is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.